Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Share-based Compensation: 2020-2025

Historic Share-based Compensation for LifeStance Health (LFST) over the last 6 years, with Q3 2025 value amounting to $18.3 million.

  • LifeStance Health's Share-based Compensation rose 2283.99% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.6 million, marking a year-over-year decrease of 499.46%. This contributed to the annual value of $76.2 million for FY2024, which is 2335.9% down from last year.
  • Latest data reveals that LifeStance Health reported Share-based Compensation of $18.3 million as of Q3 2025, which was up 2283.99% from $21.1 million recorded in Q2 2025.
  • Over the past 5 years, LifeStance Health's Share-based Compensation peaked at $108.6 million during Q4 2021, and registered a low of $605000.0 during Q1 2021.
  • In the last 5 years, LifeStance Health's Share-based Compensation had a median value of $21.5 million in 2023 and averaged $31.2 million.
  • Within the past 5 years, the most significant YoY rise in LifeStance Health's Share-based Compensation was 979338.84% (2022), while the steepest drop was 6760.1% (2022).
  • LifeStance Health's Share-based Compensation (Quarter) stood at $108.6 million in 2021, then plummeted by 67.6% to $35.2 million in 2022, then tumbled by 40.56% to $20.9 million in 2023, then fell by 22.82% to $16.1 million in 2024, then grew by 13.32% to $18.3 million in 2025.
  • Its Share-based Compensation stands at $18.3 million for Q3 2025, versus $21.1 million for Q2 2025 and $18.6 million for Q1 2025.